INCA33890

Phase 3Small molecule

Incyte

INCA33890 is one of 43 small molecule programs targeting Solid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

CRC (colorectal Cancer)Not yet recruiting

Solid TumorPhase 1

Recruiting

CRC (colorectal Cancer)Phase 3

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

INCA33890

Incyte

Phase 3

2 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 10

Carboplatin AUC-5

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Solid Tumor

NCT06179160

Q2 2029

Phase 1Recruiting

Solid Tumor

NCT05836324

Phase 2Not yet recruiting

CRC (colorectal Cancer)

NCT07823322

Q3 2029

Phase 3Recruiting

CRC (colorectal Cancer)

NCT07284849

Q4 2030

Phase 2Not yet recruiting

Head and Neck Cancer Squamous Cell Carcinoma

NCT07876414

Clinical

Trials by Indication[1]

CRC (Colorectal Cancer)2 trials

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Recruiting· Incyte logo

Incyte·Phase 3·NCT07284849·700 enrolled

A Phase 2 Study of INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy (NEXERA-204)

Not yet recruiting· Incyte logo

Incyte·Phase 2·NCT07823322·40 enrolled

Solid Tumor2 trials

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Incyte logo

Incyte·Phase 1·NCT05836324·570 enrolled

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Recruiting· Incyte logo

Incyte·Phase 1·NCT06179160·710 enrolled

Head and Neck Cancer Squamous Cell Carcinoma1 trial

A Randomized Phase 2 Trial of Anti Bispecific Antibody (INCA33890) Versus Pembrolizumab for Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TRACE)

Not yet recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT07876414·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for INCA33890. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INCA33890 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INCA33890. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Incyte company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Incyte

INCA33890

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2029

Q3 2029

Q4 2030

Trials by Indication[1]

CRC (Colorectal Cancer)2 trials

Solid Tumor2 trials

Head and Neck Cancer Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News